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Abstract
Epithelial ovarian cancer is an aggressive and deadly disease and understanding its invasion mechanisms is critical for its
treatment. We sought to study the penetration/invasion of ovarian tumor cells into extracellular matrices (ECMs) using a
fibroblast-derived three-dimensional (3D) culture model and time-lapse and confocal imaging. Twelve ovarian tumor cells
were evaluated and classified into distinct groups based on their ECM remodeling phenotypes; those that degraded the
ECM (represented by OVCAR5 cells) and those that did not (represented by OVCAR10 cells). Cells exhibiting a distinct ECM
modifying behavior were also segregated by epithelial- or mesenchymal-like phenotypes and uPA or MMP-2/MMP-9
expression. The cells, which presented epithelial-like phenotypes, penetrated the ECM using proteases and maintained
intact cell-cell interactions, while cells exhibiting mesenchymal phenotypes modified the matrices via Rho-associated serine/
threonine kinase (ROCK) in the absence of apparent cell-cell interactions. Overall, this study demonstrates that different
mechanisms of modifying matrices by ovarian tumor cells may reflect heterogeneity among tumors and emphasize the
need to systematically assess these mechanisms to better design effective therapies.
Citation: Kwon Y, Cukierman E, Godwin AK (2011) Differential Expressions of Adhesive Molecules and Proteases Define Mechanisms of Ovarian Tumor Cell Matrix
Penetration/Invasion. PLoS ONE 6(4): e18872. doi:10.1371/journal.pone.0018872
Editor: Sandra Orsulic, Cedars-Sinai Medical Center, United States of America
Received November 5, 2010; Accepted March 21, 2011; Published April 19, 2011
Copyright:  2011 Kwon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by a program project grant from Ovarian Cancer Research Fund (http://www.ocrf.org to A.K.G.) and grants from the
National Cancer Institute (NCI) and National Institutes of Health (NIH) (CA113451 to E.C. and CA140323 to A.K.G.). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Edna.Cukierman@FCCC.edu (EC); AGodwin@kumc.edu (AKG)
Introduction
Epithelial ovarian cancer (EOC), along with related Mu ¨llerian
duct adenocarcinomas of the peritoneum and fallopian tube, are
associated with the highest case/fatality ratio for all gynecologic
malignancies diagnosed and is the fifth leading cause of cancer
death in women in the U.S. [1]. Delay in diagnosing ovarian
cancer is common, since the disease confined to the ovary seldom
produces symptoms. As a result, the majority of cancers are
diagnosed when the cancer involves one or both ovaries and is
actively spreading beyond the pelvis to the lining of the abdomen
and/or to adjacent lymph nodes [2,3]. Therefore, understanding
invasion strategies of ovarian cancer cells is important for the
clinical management of ovarian cancer.
EOCs are considered to arise from the ovarian surface
epithelium (OSE), a monolayer of cells that overlies the ovary
and lines postovulatory inclusion cysts [4] or the fallopian tube in
some hereditary cases [2]. Once an ovarian epithelial cell
undergoes transformation, it detaches from the underlying matrix
and can spread, often in clusters, by direct extension to adjacent
organs [5]. Dissemination of EOC cells through the vasculature is
generally rare, although the presence of metastases in extra-
peritoneal sites (e.g., bone marrow, brain, and liver) has been
reported in advanced-stage disease [6,7,8]. Ovarian tumor cells
appear more likely to exfoliate and be transported by normal
peritoneal fluid as multi-cellular aggregates [5,9]. Exfoliated cells
are implanted through discrete steps; adhesion to mesothelial cells,
penetration or invasion throughout the peritoneal cavity, the
omentum and the peritoneum [5]. The precise molecular
mechanisms that control the penetrating invasion into the stroma
and consequent dissemination to the peritoneum are unknown.
Some studies suggest that the loss of E-cadherin expression could
be involved in this process [9,10] as tumor cells, including EOC
cells, are often thought to undergo epithelial to mesenchymal
transition (EMT) and invade as single cells through the stroma.
However, several lines of evidences suggest that EOC cells may
invade using strategies other than the traditional EMT mechanism.
First, more often than not, ovarian tumors are characterized by
pathological criteria as invasive and malignant, yet they maintain E-
cadherin expression [11,12]. In addition, EOC and normal OSE are
distinct from other epithelial cell-derived cancers and other normal
epithelia, respectively. Remarkably, human normal OSE present both
epithelial and mesenchymal phenotypes [4,5] whereas they often lose
mesenchymal characteristics and increase E-cadherin protein levels as
these normal epithelial cells become malignant [4,9,11,13,14].
Moreover, the relevance of traditional EMT as a major invasion
mechanism in vivo has been challenged [15,16]. Therefore, besides well-
studied mesenchymal cell migration accompanied by EMT, ovarian
cancer cells may invade through additional mechanisms.
Recent studies demonstrated that in the absence of EMT, many
types of cancer cells can invade as single cells without the use
of proteolysis (e.g., amoeboid cell migration) or as collective
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cell migration as well as collective growth) [17]. In the collective
cell migration strategy, cells move as groups consisting of multiple
cells connected through cell-cell junctions [18,19,20]. This type of
movement occurs in vivo during morphogenesis and wound repair
[19]. Also, it has long been observed that biopsies in cancer
patients often contain groups of cells which either maintain
contact with primary site (protruding sheets or strands) or are
detached from their origin (nests) [19,21]. These collective cells are
known to rely on proteolysis to move through ECMs [22,23].
Different from proteolysis-dependent collective or mesenchymal
single cell invasion, protease-independent amoeboid invasion
mechanism has been described in cancer cells and sarcoma cells
upon treatments with protease inhibitors [24,25,26]. It was also
reported that many types of cancer cells, which do not express
appreciable amount of ECM-degrading proteases, can invade
using the amoeboid strategy [26,27]. In amoeboid invasion, the
up-regulation of Rho and Rho-associated serine/threonine kinase
(ROCK) is considered to be responsible for the generation of
actomyosin forces that allow rounded and blebbing cancer cells to
contract matrices and push their cell bodies through ECM fibers
[25,26].
In this study, we evaluated how ovarian tumor cell lines
penetrate or invade through ECM using a three-dimensional (3D)
culture model to mimic stroma in vivo conditions [28,29,30]. We
report that ovarian tumor cells invade the mesenchymal/
connective tissue-like ECM using primarily two distinct strategies;
some cells appear to degrade the ECM using collective cell
migration mechanisms whereas others form less tight cell-cell
interactions and invade through the ECM by rearrangement (or
possible contraction) of the ECM substrate. Protein profiles of
epithelial and mesenchymal cell markers helped defining the
invasion mechanisms utilized by the various cells. Penetration/
invasion of cells with epithelial cell characteristics (e.g., OVCAR5)
was mainly repressed by protease inhibitors while invasion of cells
which exhibited a more mesenchymal marker expression profile
(e.g., OVCAR10) was suppressed by ROCK but not protease
inhibitors. Our study suggests that characterization of the
penetrating/invading strategy used by ovarian cancer cells is
required to select adequate therapies that will effectively target
ovarian cancer behavior.
Results
Ovarian tumor cells penetrate (i.e., invade) through ECMs
using primarily two different mechanisms
We used a well studied fibroblast-derived 3D culture model to
examine how various ovarian tumor cells penetrate or invade
through an underlying in vivo-like 3D ECM [28,29,30,31]. NIH-
3T3 fibroblast (N3F)-derived matrices were used for the majority
of analyses since this cell line reproducibly produced uniformly
thick ECMs. Similar results were produced using matrices derived
from tumor-associated fibroblast (TAFs, see Materials and
Methods for details) in pilot studies (limited data are shown
below). Twelve ovarian tumor cell lines were plated onto pre-
stained N3F-derived matrices while cell-induced matrix changes
were recorded and analyzed over time. All tumor cell lines but
SKOV3 showed rounded morphologies when cultured within 3D
matrices. Most tumor cells organized in cell clusters within the
matrices with exceptions of SKOV3 and UPN251 which
maintained a single cell configuration at early culturing times
(data not shown). Using fluorescently pre-labeled ECM, we
observed that cells with the tendency of forming clusters or
agglomerates could greatly remodel the ECM compared to cells
that remained as single cells (see bottom panels in Figure 1A–E for
qualitative images).
Among the cells forming clusters including OVCAR5 and
OVCAR10 (Figure 1A & B), the marked difference in their effects
on the pre-labeled ECM allowed to categorize a majority of them
into two groups. One group of cells, represented by OVCAR5,
appeared to degrade the pre-labeled ECM, showing a diminished
intensity of the ECM fibers immediately underneath the cell
clusters (compare bottom panels of Figure 1A with 1F). The other
group, represented by OVCAR10, appeared to reorganize the
pre-labeled ECM as if the cells caused ‘pulling’ of ECM fibers
towards areas rich in cell density, consequently exhibiting stronger
fluorescent intensities in the immediate vicinity of the cell clusters
(compare bottom panels of Figure 1B with 1F). These two cell
groups represented by OVCAR5 and OVCAR10 can also be
classified by their capability to form cell-cell interactions – the
more tightly connected cells were grouped together with
OVCAR5. Cells exhibiting OVCAR5-like phenotype included
OVCAR2, OVCAR3, OVCAR4, PEO1, and PEO4 (Figure 1C).
In contrast, A2780, and its platinum resistant sub-clones, CP70
and C30 cells [32] presented less tight clustering and matrix
modification phenotypes similar to the ones observed in
OVCAR10 (Figure 1E). A2780 cells also showed a degree of
heterogeneity in their modifying effects on the matrices and
thereby exhibited a mixed phenotype. SKOV3 and UPN251 cells
(which did not form clusters) more closely resembled OVCAR5 as
compared to OVCAR10 in their ability to modify ECMs
(Figure 1D).
Protease and adhesion molecule profiles differ in the two
distinct matrix-modifying groups
To test if epithelial/mesenchymal and protease expression
patterns could predict the type of matrix modification behaviors
imparted by the various cells, we decided to assess the expression
of epithelial and mesenchymal protein markers and the presence
of various proteases in the panel of ovarian tumor cell lines grown
under 2D conditions using Western blot analyses. We also
included immortalized, non-tumorigenic human ovarian epitheli-
um cells, HIO-80 and HIO-114 [33,34], and human primary
normal ovarian fibroblast, HFNO402 and HFNO502, as ovarian
epithelial and mesenchymal cell controls.
As seen in Figure 2, the majority of the cells originally grouped
with OVCAR5, with the exception of PEO4, expressed high levels
of E-cadherin and keratins (an anti-pan-keratin antibody was
used). In addition, these cells contained low or undetectable levels
of mesenchymal markers, such as N-cadherin and vimentin, as
well as ZEB-1, a transcriptional repressor of E-cadherin (Figure 2).
Interestingly, PEO4 cells showed an expression pattern that is
more representative of mesenchymal cells, similar to expression
patterns seen in OVCAR10 cells. Indeed, cells grouped with
OVCAR10 expressed vimentin and ZEB-1 and commonly lacked
expression of both E-cadherin and pan-keratin (Figure 2). N-
cadherin expression levels were inconsistent among cells grouped
with OVCAR10, showing little or no expression in CP70, higher
in C30, and intermediate in OVCAR10 and A2780 (Figure 2). As
compared to cells forming clusters, SKOV3 and UPN251 cells
presented with a mixed epithelial/mesenchymal phenotypes,
similar patterns to the immortalized non-tumorigenic ovarian
epithelial cells, HIO-80 and HIO-114. They expressed both
keratin and vimentin but lacked the expression of E-cadherin. As
expected, normal human ovarian epithelial cells (HIO’s-) and
fibroblasts (HFNO’s-) presented patterns known to be associated
with mesenchymal phenotypes while normal ovarian epithelial
cells express keratins. Also, all cells but the normal ovarian
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18872Figure 1. Differential ECM modifying mechanisms of ovarian tumor cells. A panel of ovarian tumor cells was plated onto pre-stained N3F-
derived matrices and phase contrast (cells, top panel) and fluorescence (matrices, bottom panel) images were acquired over time during the culturing
of cells. Depending on appearance of cell-cell interactions and ECM modifications induced during culturing cells within matrices, cells were divided
largely into 3 different categories. OVCAR5 (A) and OVCAR10 (B) cells that represent the two primary ECM remodeling phenotypes are enlarged for
the comparison. Some cells including OVCAR5 looked very tightly connected and their growth within ECMs resulted in degradation of the ECM (A &
C). Other cells appeared to degrade the ECM while they organized in a single-cell configuration at early culturing times (D). Lastly, cells in the third
category including OVCAR10 formed less tight cell-cell interactions than cells grouped with OVCAR5 while ECMs appeared to be rearranged,
accumulated, or contracted (B & E). Matrices maintained without cells did not undergo remodeling (F). Images shown are representatives of each cell
line and its corresponding ECMs after 10 days of culturing. Bar represents 200 mm.
doi:10.1371/journal.pone.0018872.g001
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1, zona occluden-1 (ZO-1), and claudin-1 (Figure 2).
Additional differences between the two groups of cells were
observed when patterns of protease expressions were assessed.
MMP-2 and MMP-9 (pro-forms) were expressed at higher levels in
cells that presented the OVCAR10 phenotype with the exception
of PEO4 (Figure 2). Conversely, expression of the pro-form of
urokinase-type plasminogen activator (uPA) was elevated in
OVCAR5-like cells again with the exception of PEO4 (Figure 2).
Active forms of membrane type 1 metalloprotease (MT1-MMP)
expression levels varied but were more frequently observed in
OVCAR5-like cells. b1-integrin expression patterns did not clearly
delineate the two primary groups forming cell clusters but the
expression was higher in SKOV3 and UPN251 that grew as single
cells. The expression patterns of epithelial/mesenchymal protein
markers were similar as observed in 2D when OVCAR5 and
OVCA10 cells were cultured in 3D conditions using either N3F-
or TAF-derived matrices (Figure S1).
Localization patterns of adhesion molecules and
cytoskeleton are cell type-dependent
We next evaluated the localization patterns of E-cadherin, b1-
integrin, and F-actin in cells cultured within N3F-derived ECMs
using indirect immunofluorescence. OVCAR5 cells (which seemed
to have a tight cluster phenotype) presented clear membranous E-
cadherin and b1-integrin localizations at cell-cell contacts as well
as cortical actin patterns, all suggestive of classic epithelial
phenotypes that contain clear cell-cell adhesion structures
(Figure 3A). In contrast, OVCAR10 cells presented no detectable
E-cadherin labeling at their cell membranes while b1-integrin and
F-actin expressions were more representative of mesenchymal-like
phenotypes; presenting patched or punctuated patterns somewhat
reminiscent of cell-matrix adhesion structures (Figure 3B). These
differential expression patterns of adhesion molecules and
cytoskeletal proteins further supported our beliefs that the
presence of epithelial- or mesenchymal-like phenotypes adapted
by the two types of ovarian tumor cells could contribute to cell-
type dependent penetration/invasion strategies.
Remodeling phenotypes of the ECM, indicative of
penetration/invasion strategy, are cell-type specific
Using time-lapse microscopy, we acquired images of pre-labeled
N3F-derived ECMs before and after plating OVCAR5 and
OVCAR10 cells. Matrices maintained in the absence of cells did
not change over time (Figure 4A). However, in the presence of
OVCAR5 cells, matrices were degraded over time and the pre-
labeled material became almost undetectable following 10 days of
culture (Figure 4A). In comparison, OVCAR10 cells appeared to
have accumulated matrix fibers towards their proximity over time,
resulting in areas which have increased fluorescent intensities
(Figure 4A). Next, we conducted a similar experiment using TAF
pre-labeled ECMs. The phenotypes observed using these matrices
closely resembled the ones observed with N3F-derived matrices
(Figure 4B).
Since OVCAR5 and OVCAR10 cells induced distinct changes
on the pre-labeled ECM, we next examined whether these
changes were imparted upon ECM protein in general (total matrix
protein, TMP) or specifically to fibronectin. Fibronectin is one of
the main components of matrices derived from fibroblasts and
known for its importance in regulating matrix dynamics and
Figure 2. Expression of epithelial and mesenchymal markers and proteases in a panel of ovarian tumor cells. Ovarian tumor cell lysates
isolated from cells grown in 2D were subjected to SDS-PAGE and immunoblotting. Cells were grouped according to their ECM remodeling
capabilities shown in Figure 1. Human immortalized ovarian epithelium (HIO) and human fibroblasts derived from normal ovaries (HFNO) were used
as epithelial and mesenchymal cell controls. Bands corresponding to pro-forms of uPA (55 kDa), MMP-2 (68 kDa), and MMP-9 (90 kDa) and active
forms of MT1-MMP (55 kDa) were detected. Levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression were used as protein loading
controls.
doi:10.1371/journal.pone.0018872.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18872Figure 3. Expression patterns of E-cadherin, b1-integrin, and F-actin in OVCAR5 vs. OVCAR10 cells. OVCAR5 (A) and OVCAR10 (B) cells
were plated onto N3F-derived matrices and stained for E-cadherin (top panel), b1-integrin (middle panel), and F-actin (bottom panel). Nuclei (blue)
are shown to the right side of each panel. Bar represents 50 mm.
doi:10.1371/journal.pone.0018872.g003
Figure 4. Time-lapse imaging of ECM remodeling induced by OVCAR5 or OVCAR10 cells. Pre-stained N3F- (A) or TAF-derived matrices (B)
were maintained without cells or plated with OVCAR5 or OVCAR10 cells. Randomly selected locations were consistently tracked over time. Images
shown were acquired on days 0 (top panel), 7 (middle panel), and 10 (bottom panel). Phase contrast (cells, left panel) and fluorescence (pre-labeled
ECM, right panel) images are shown. Bar represents 200 mm.
doi:10.1371/journal.pone.0018872.g004
Invasion Mechanisms of Ovarian Tumor Cells in 3D
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18872collagen deposition [35,36,37]. Cells were plated onto TMP pre-
labeled N3F-derived ECMs. Following 7 days of culture, matrices
were re-stained selectively for fibronectin using a polyclonal
antibody and nuclei were identified using 49,6-diamidino-2-
phenylindole (DAPI). Fluorescent intensities obtained from labeled
TMP or fibronectin were compared while assessing cell-containing
and adjacent (i.e., cell-devoid) areas in the same field using
reconstituted projection images of the 3D cultures. The intensity of
fibronectin and to a lesser degree, of pre-labeled TMP was
considerably lower beneath OVCAR5 cell clusters compared to
the adjacent cell-devoid areas (Figure 5A & B). Matrix thickness
was greatly reduced in an OVCAR5-dependent manner (compare
areas containing nuclei (blue) and areas with no nuclei in Figure 5C
& D), indicating a possible degradation and/or displacement of
ECMs by these cells.
Conversely, the fluorescent intensity corresponding to fibronec-
tin and TMP did not seem to be greatly affected by OVCAR10
cells although for fibronectin there were indications of decrease in
fluorescent intensity in some areas containing nuclei (Figure 5E &
F). Accordingly, OVCAR10 cells did not seem to have caused
appreciable change in the thickness of matrices (compare signals
derived from matrix (green or red) between areas containing nuclei
(blue) and areas with no nuclei in Figure 5G & H). Interestingly,
matrix accumulation was evident on top of OVCAR10 cells, but
not OVCAR5, (e.g., green and red traces on top of the nuclei
(blue) in Figure 5G & H), suggesting the use of different strategies
by the two cell groups to invade/penetrate through the ECM.
When reconstituted projection images of the 3D cultures were
produced to represent the topographical top, middle, and bottom
layers as shown in Figure 5I–L, the biggest difference induced by
the two cell types to the matrices was observed again in the ‘top’
layers of the matrix. For example, no matrix was detected in areas
containing OVCAR5 cells (Figure 5I & J) while intense signals
were detected for OVCAR10 cells (Figure 5K & L, see patches of
red). This cell type-dependent difference in the ‘top’ of matrices
was observed both in fibronectin and TMP. When levels of
fluorescent intensities obtained from TMP or fibronectin staining
were quantified, results revealed that cell-containing areas retained
28% vs. 244% of fibronectin intensities (Figure 5M) and 258% vs.
2,596% of TMP intensities (Figure 5N) for OVCAR5 and
OVCAR10 cells, respectively, relative to the levels detected from
cell-devoid areas at the top layer. Therefore, OVCAR10 cell-
containing areas presented approximately 10-fold higher intensity
levels than OVCAR5 cell-containing areas relative to their cell-
voided areas.
OVCAR5- and OVCAR10-induced ECM-remodeling is
dependent on the activities of proteases or ROCK,
respectively
To investigate whether the cells utilize strategies that depend on
ECM-degrading enzymes, integrin and/or Rho activities, we
decided to assess the topographical patterns of N3F-derived ECMs
modified by OVCAR5 and OVCAR10 in the presence or absence
of b1-integrin, ROCK and different protease inhibitors. We
estimated cell-induced changes of TMP and fibronectin at the
three matrix locations, top, middle, and bottom under the various
inhibitory conditions using confocal microscopy and image
analysis as described above.
OVCAR5-mediated TMP degradation (reduction of fluorescent
intensity) was significantly suppressed upon treatment with
aprotinin (serine protease inhibitor), a protease inhibitor cocktail
(PI), and a mixture of PI and ROCK inhibitor, H1152, (PRI) as
compared to untreated cells (Figure 6A and Table S1). In contrast,
GM6001 (a broad spectrum MMP inhibitor) had negligible effects
on TMP intensity changes while treatment of amiloride (a specific
inhibitor of uPA) seemed to activate or induce additional
degradation (Table S1). Therefore, we concluded that the
suppression of TMP degradation by OVCAR5 cells depended
on the type of protease used by the cells. Effects of protease
inhibitors also appeared to be affected by ECM components.
Different from TMP, fibronectin intensity was not significantly
affected by the presence of protease inhibitors in OVCAR5 cell-
mediated invasion - only PI (Figure 6B) and b1-integrin antibody
(Table S2) were able to significantly reduce fibronectin degrada-
tion and their effects were limited only to the ‘top’ layer. In
comparison, TMP and fibronectin were similarly affected by
inhibitors used in the presence of OVCAR10 cells. OVCAR10-
induced intensity changes on the ECM were largely suppressed by
ROCK inhibition using H1152 or Y27643 and by PRI (Figure 6C
& D and Tables S3 & 4). However, none of protease inhibitors
tested effectively inhibited OVCAR10-induced intensity changes
(Figure 6C & D and Tables S3 & 4).
Furthermore, there was a strong correlation between the TMP
confocal microscopy data and results obtained using epifluores-
cence microscopy. The penetration/invasion of OVCAR5 cells
within N3F-derived ECMs could be inhibited in the presence of
aprotinin, PI, and PRI, while leupeptin, GM6001, or amiloride
did not effectively suppress the OVCAR5-induced ECM degra-
dation; i.e., the resultant ECMs appeared to be impossible to
differentiate from the ones using untreated controls (Figure S2A).
Conversely, none of the protease inhibitors tested appeared to
effectively inhibit OVCAR10-induced ECM changes (Figure S2B).
ROCK inhibitors (Y27632 and H1152) did not show any effects
on OVCAR5-induced ECM modifications (Figure S2A), while
these inhibitors clearly reduced ECM changes induced by
OVCAR10 cells (Figure S2B). Finally, the functional blockage of
b1-integrin did not appear to affect either OVCAR5- or
OVCAR10-induced changes to the underlying ECM (Figure
S2A & B). In all cases, controls using vehicle (DMSO) or non-
specific IgG antibodies did not affect the cell-induced matrix
modification (data not shown).
The inhibitory effect of protease and ROCK inhibitors was next
evaluated in an expanded panel of ovarian tumor cells.
Epifluorescence images of pre-labeled N3F-derived matrices
indicated that the ECM modification induced by OVCAR3 and
OVCAR4 cells were largely inhibited by aprotinin but not H1152
(Figure S3A). Conversely, ECM accumulation induced by CP70
and C30 was inhibited by H1152 whereas aprotinin did not affect
(Figure S3B). Therefore, cell-induced ECM degradation was
inhibited by aprotinin while ECM contraction was suppressed by
H1152.
Cells that degrade ECMs secrete higher caseinolytic
enzymes than cells that tend to contract ECMs
ROCK and protease activities were assessed in cells grown in
either 2D or 3D conditions and compared the result with the
sensitivity to protease and ROCK inhibitors. Zymography was used
to detect protease activity of conditioned media derived from cells
representing the ECM modifying phenotypes. Interestingly, OV-
CAR5, OVCAR4, and SKOV3 cells that degrade the ECM as
either group or single cells secreted higher levels of caseinolytic
proteases both in 2D and 3D (N3F-derived ECMs) cultures as
compared toOVCAR10 andC30cellsthat causeECMcontraction
(Figure 7A). This difference was even more apparent in 3D
conditions where caseinolytic enzyme species lower than size of
50 kDa appeared to be highly activated (Figure 7A). Similarly,
OVCAR5, OVCAR4, and SKOV3 cells appeared to secrete more
gelatinolyticproteasesin3Dcomparedto2Dconditions(Figure7B).
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gelatinolytic enzymes (Figure 7B). Overall, protease activities
derived from OVCAR10 and C30 cells were minimal and did
not appear to be further induced under the 3D condition (Figure 7A
& B). These results correlated well with the observation that
aprotinin inhibit ECM modification by OVCAR5- but not
OVCAR10-like cells (Figure S3A & B). Also, the result implicates
that MMP inhibitors may not be effective in inhibition of ECM
remodeling by either groups of cell that secret low levels of
gelatinolytic enzymes (Figure 7B). Cells that degrade ECMs
contained multiple caseinolytic enzyme species (Figure 7A) not
inhibited by a specific uPA inhibitor (Figure S4), explaining the lack
of inhibition of ECM degradation by amiloride (Figure S2A and
Tables S1 & 2).
Figure 6. Effect of protease and ROCK inhibitors on total matrix protein (TMP) and fibronectin changes induced by OVCAR5 or
OVCAR10 cells. OVCAR5 (A & B) and OVCAR10 (C & D) cells were plated onto pre-labeled N3F-derived matrices and stained for fibronectin and
nuclei following 7 days of culturing under various inhibitor conditions. Images of TMP, fibronectin and nuclei staining were acquired using confocal
microscopy and analyzed as described in Figure 5. Confocal images were reconstituted to represent the top, middle and bottom layers of the 3D
cultures. Fluorescent intensity derived from TMP (A & C) and fibronectin (B & D) staining was measured. Cell-induced intensity change was estimated
by calculating the ratio of area corresponding to intensities that ranged between 90 and 225 (high intensity) to areas with intensities below 90 (low
intensity) in both cell-containing and adjacent cell-absent areas in the same field. Data (mean 6 SE, n=5,10) were presented relative to intensity
change at the bottom of 3D culture (100) in the absence of inhibitors (untreated control). Asterisks (*) represent significant differences (p#0.01)
compared to untreated controls using ANOVA for the top, middle, and bottom of matrices. Concentrations of inhibitors used were selected to avoid
measurable inhibition of cell proliferation. PI; a protease inhibitor cocktail of individual protease inhibitors containing aprotinin (7.5 mM), leupeptin
(20 mM), and GM6001 (25 mM), PRI; a mixture of PI and H1152 (0.1 mM). Refer to Table S1, Table S2, Table S3, and Table S4 for entire inhibitors tested
and multiple comparisons among groups treated with different inhibitors.
doi:10.1371/journal.pone.0018872.g006
Figure 5. OVCAR5 or OVCAR10 cell-induced modifications in total matrix protein (TMP) and fibronectin. OVCAR5 (A–D) or OVCAR10
(E–H) cells were cultured within pre-stained N3F-derived matrices (red) for a period of 7 days and then fibronectin (green) and nuclei (blue) were
detected by indirect immunofluorescence (green) and DAPI staining (blue), respectively. Images were acquired using a multiple focal plane image
acquisition function to scan all files in the Z axes for each field. An XY view of 3D reconstituted maximum projections of fibronectin (A & E) and TMP (B
& F) are shown. The yellow line depicts the area where the stacked images were analyzed to produce the two channel histograms shown and
reconstituted to portray a maximum projection of the stack using an XZ 10 mm thick reconstitution view (C, D, G, & H). In addition, stacks were
partially reconstituted into maximum XY projections using only the files corresponding to the top, middle, and bottom layers of the 3D cultures (see
Materials and Methods for details). The resulting projections were pseudo-colored to match fluorescent intensity levels (I–L). Using a scale that
comprises 225 levels of intensity, red/white colors depict higher intensity levels while blue/black colors depict lower intensities of fibronectin( I&K )
and TMP (J & L) which were obtained in cultures containing OVCAR5 (I & J) or OVCAR10 (K & L) cells. Intensity changes induced by OVCAR5 (M) and
OVCAR10 (N) cells were estimated by calculating the ratio of area corresponding to intensities that ranged between 90 and 225 (high intensity) to
areas with intensities below 90 (low intensity) in both cell-containing and adjacent cell-absent areas in the same field. Cell-induced intensity change
was expressed as percent difference of the ratio in cell-containing area relative to cell-absent area (100%, dotted line). Note, matrix degradation in
OVCAR5 containing areas, versus accumulation of matrix by OVCAR10 cells as compared to adjacent cell-devoid area. Bar represents 100 mm.
doi:10.1371/journal.pone.0018872.g005
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with cell type-dependent inhibitory effect of the ROCK inhibitors.
ROCK activities were similar among cells cultured in either 2D or
3D (N3F-derived matrices) conditions with the exception of
OVCAR2, SKOV3, and UPN251 cells (Figure S5). Therefore,
cellular levels of ROCK activity alone did not appear to correlate
well with cell type-dependent ECM modifying phenotypes.
Discussion
Ovarian cancer is a highly aggressive disease, making inhibition
of adjacent organ penetration/invasion, which facilitates the
dissemination of this cancer, an important therapeutic goal.
Mesenchymal cell migration accompanied by EMT has been
suggested to be the major invasion mechanism of ovarian cancer
cells [9]. However, recent studies, using 3D culture models,
revealed that cancer cells can use additional strategies to invade
through tissues [17,26,38]. As such, cells have been shown to be
capable of invading without disrupting cell-cell interactions (i.e.,
collective cell migration) or to penetrate the ECM without major
protease or integrin dependencies (i.e., amoeboid cell migration)
[23]. Since ovarian cancer cells often acquire a peculiar phenotype
which includes up-regulation of E-cadherin expression in contrast
to its absence in normal OSE [4], we hypothesized that these cells
may penetrate/invade through ECMs using alternative strategies
to the well-studied mesenchymal cell migration. Therefore, the
matrix remodeling capabilities of a panel of ovarian tumor cell
lines was assessed using fibroblast-derived matrices, to mimic
ECMs of in vivo environments [30].
Different ECM topographic changes were induced by various
tumor cells. A group of cells, represented by OVCAR5, appeared
to have degraded the ECM. They also seemed to maintain their
cell-cell contact while they invaded through ECMs (Figure 1A &
C) and clearly expressed cell-cell adhesion markers (Figures 2 &
3A). The other primary group, represented by OVCAR10,
appeared to modify the ECM by a massive rearrangement (e.g.,
contraction or accumulation) of the ECM (Figure 1B & E). These
cells presented a more loose agglomeration (Figures 2 & 3B). A
potential third group, i.e., SKOV3 and UPN251, appeared to
behave in a single cell manner with less clear impairment or
remodeling upon ECMs (Figure 1D). Some of previous studies
suggested that cell morphology implicates cell invasion strategies
[17,23,24]. However, in our study, most of tumor cell lines
presented an epithelial phenotype in 2D cultures and showed
rounded morphology within the matrices suggesting that cell
morphology itself may not be sufficient to predict the type of ECM
remodeling and subsequently, the penetration/invasion strategy.
We conducted similar studies using human ovarian fibroblast-
derived matrices. Although it was less apparent, tumor cells (e.g.,
OVCAR5 and OVCAR10) presented similar ECM modifying
effect as observed in N3F- or TAF-derived matrices (data not
shown). Human fibroblasts produced matrices visibly very
different from N3F-derived matrices when they were fluorescently
stained, i.e., substantially thinner and less uniform, making it more
difficult to assess cell behavior. In addition, differences in
architecture of the ECM as well as protein composition might
explain differences between the ECM modifying behavior on N3F-
and human fibroblast-derived matrices. For instance, cancer cells
Figure 7. Differential activity of caseinolytic and gelatinolytic enzymes secreted by cells grouped according to their ECM
remodeling phenotypes. Representative cells in each ECM remodeling category were cultured in 2D (top panels) and 3D (N3F-derived matrices,
bottom panels) conditions. Conditioned media were subjected to SDS-PAGE using gels copolymerized with casein and plasminogen (A) or gelatin (B).
Trypsin and collagenase were used as positive controls of caseinolytic and gelatinolytic activity, respectively. Note that culturing OVCAR5, OVCAR4,
and SKOV3 cells in 3D conditions increased caseinolytic activity, especially enzyme species in the molecular weight range of 30,50 kDa.
doi:10.1371/journal.pone.0018872.g007
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therefore, they are likely to rely on ECM-degrading enzymes to
invade through rigid ECMs. Also, cells may prefer invading
through N3F-derived matrices which lack type I collagen, which is
more resistant to enzymatic degradation than other ECM
components (e.g., fibronectin), compared to human fibroblast-
derived matrices rich in type I collagen (data not shown).
We conducted most of our studies using cells that represented
the two distinct phenotypes of collective agglomerates within
ECMs, OVCAR5 and OVCAR10. These cells induced strikingly
different topographic changes to the ECM while making their way
through these substrates (Figures 4 & 5). We believe that the
matrix remodeling phenotype could be used to assess penetration/
invasion strategies. For example, based on matrix remodeling
phenotypes, OVCAR5 cells fit into a ‘collective cell migration’
category where cells migrate as groups and use ECM-degrading
proteases for their invasion [17]. In fact, this phenotype was also
observed when OVCAR5 cells were evaluated as spheroids
invading through a monolayer of mesothelial cells [40], thus
confirming the relevance of our approach. Collective cell
migration has also been demonstrated in colon cancer cells by
Nabeshima and colleagues [22,41,42,43]. Their study showed that
the expression of ECM-degrading proteases, such as MT1-MMP
and MMP-2 at the leading edge of the cell aggregates are critical
for cohort migration, a type of collective cell movement [22].
More recently, it was reported that podoplanin, a plasma
membrane glycoprotein, induces tumor cell migration and
invasion without disrupting E-cadherin-mediated cell-cell junction
both in vitro and in a transgenic model of carcinogenesis in vivo [12].
In contrast, ECM rearrangement mediated by OVCAR10 cells,
similar to patterns of collagen contraction induced by mesenchy-
mal cells [44,45] did not seem to either rely on proteases or present
tight cell-cell interaction as seen in OVCAR5. In addition, protein
localization patterns of E-cadherin, b1-integrin, and F-actin of the
two cell lines suggested that OVCAR5 and OVCAR10 cells
indeed present epithelial vs. mesenchymal phenotypes, respectively
(Figure 3A & B). b1-integrin expression at cell-cell contact in
OVCAR5 cells (Figure 3A) also indicated very tight cell-cell
interactions [46].
Evaluation of protein expression profiles further confirmed
epithelial and mesenchymal characteristics of two groups of cells
represented by OVCAR5 and OVCAR10. All cells grouped
together with OVCAR5, except for PEO4, showed a distinct
epithelial phenotype, i.e., expressed E-cadherin and pan-keratin
with little or no expression of vimentin, N-cadherin, and ZEB-1,
an E-cadherin repressor (Figure 2). Conversely, cells grouped with
OVCAR10 cells expressed a battery of proteins reminiscent to
those expressed in mesenchymal cells, i.e., expressed vimentin and
ZEB-1 but lacked pan-keratin and E-cadherin. Nevertheless, these
cells also presented some epithelial markers such as claudin-1, ZO-
1, and occludin-1, which are typically localized at tight junctions
and are often lost during EMT [47], suggesting that this cell may
be in partial EMT [48,49]. We also found differences in protease
profiles among the cells with the abovementioned epithelial and
partial EMT phenotypes (Figure 2). For example, uPA (pro-form)
was only expressed in cells that presented the epithelial properties.
Most of the ovarian tumor cells expressed MMP-2 and MMP-9
(pro-forms) weakly as previously observed [50]; however, the
tumor cells with partial EMT phenotypes had higher levels.
Therefore, the two groups could be divided by the differential
protease profile as well. Nevertheless, inhibitors of these proteases
did not seem to have an effect in reversing any of the two
phenotypes studied probably due to differences between cellular
expression levels and secreted protease activity as discussed below.
In contrast, b1-integrin expression was relatively uninformative in
grouping OVCAR5- and OVCAR10-like cells (Figure 2). How-
ever, we did observe that b1-integrin expression might be useful to
discriminate cells degrading ECM as single cells (SKOV3 and
UPN251) from those that induce ECM rearrangement (e.g.,
OVCAR10). Previous studies have reported that b1-integrin
expression is reduced in protease-independent amoeboid cell
migration compared to protease-dependent mesenchymal cell
migration [24].
Overall, our studies demonstrated that protein expression
profiles of adhesion molecules, cytokeratin, and proteases could
predict the strategy of penetration/invasion using an in vitro 3D
model, although, there were some exceptions. As discussed, PEO4
cells were grouped with OVCAR5 cells based on their ECM
remodeling properties (Figure 1C); however, their protein profile
was similar to OVCAR10 cells (Figure 2). We speculate that the
ECM change induced by PEO4 cells might be smaller than other
cells presenting OVCAR10-like phenotypes; thereby, they might
not be grouped correctly based on detection of fluorescent signal
after prolonged culture. Importantly, PEO1 and PEO4 cell lines
were obtained from the same patient before and after the onset of
resistance to chemotherapy [35,51], and may be reflective of a
major problem in treating ovarian cancer patients, i.e., the
subsequent development of drug resistance and recurrence of
cancer in spite of initial effectiveness of platinum-based chemo-
therapies [52]. One can speculate that platinum-based chemo-
therapy might result in the switching of a given invasion
mechanism and evolvement of additional strategies. Nevertheless,
these types of questions are beyond the scope of this study.
Based on the above observed characteristics, we anticipated that
ECM modification induced by OVCAR5 cells would be blocked
by protease inhibitors, while ROCK inhibitors would suppress
ECM modifications imparted by OVCAR10 cells which may have
an ability to generate force to contract ECMs. The contraction of
actin filament is known to be primarily induced by small G-protein
Rho and its downstream effector, ROCK, responsible for protease
independent invasion (e.g., amoeboid) [53,54,55,56]. Upon
exposure to inhibitors of different proteases, the degradation of
TMP by OVCAR5 cells was greatly prevented. However, the
effect was protease type-dependent. Aprotinin, a serine protease
inhibitor, effectively inhibited OVCAR5 cell-mediated TMP
degradation (Figures 6A & S2A). In contrast, the effect of
leupeptin, which inhibits both serine and cysteine proteases was
minimal, as was GM6001, a broad range MMP inhibitor. These
results correlated with the detection of massive caseinolytic but
negligible gelatinolytic proteases secreted by OVCAR5 cells
cultured within N3F-derived matrices (Figure 7A & B). We
expected that amiloride, known to specifically inhibit uPA but not
tPA [57], would effectively prevent OVCAR5 cells from degrading
the ECM since these cell type expressed higher uPA (Figure 2).
However, amiloride appeared to enhance TMP degradation
(Table S1). In fact, OVCAR5 cell-conditioned media contained
caseinolytic proteases not inhibited by amiloride especially at
molecular weight above 50 kDa (Figure S4). Noticeably, no
protease inhibitors effectively prevent fibronectin degradation by
OVCAR5 cells (Figure 6B and Table S2), implying that
fibronectin may be more susceptible to enzymatic degradation
and substrates of many different types of proteases. These results
suggest that different proteases have specificities for different ECM
components and that it will be important to determine protease
type secreted by both tumor and stromal cells to predict their
specific ECM remodeling strategies.
ROCK inhibitors blocked OVCAR10 cell-induced invasion
and ECM contraction (Figures 6C & D and S2B). However, cells
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ROCK activity as measured by an enzymatic immunoassay
(Figure S5). It has been reported that invasion of cells which did
not express ROCK or Rho at high levels were also inhibited by a
ROCK inhibitor [58]. Therefore, other mechanisms regulating
ROCK activity may be responsible for ROCK-dependent ECM
modification by these cells. MMP activity has been considered to
be implicated in collagen gel contraction and tissue reorganization
as well [59,60,61]. However, the effect of GM6001 was negligible
on ECM contraction by OVCAR10 cells in our study, as observed
previously in Hey and ES-2 ovarian tumor cells [62]. Also, the
addition of a cocktail of protease inhibitors did not seem to further
enhance the inhibitory effect of the ROCK inhibitors (Figure 6C
& D), and therefore, none of the protease inhibitors we tested
appeared to be effective in OVCAR10-induced matrix change.
This might be explained by low protease activity derived from
these cells (Figure 7A & B). Importantly, aprotinin and H1152,
which effectively inhibited OVCAR5- and OVCAR10-induced
ECM modification, respectively, also inhibited ECM changes
induced by other cells grouped together (Figure S3A & B).
Therefore, two different cell types divided by epithelial and
mesenchymal phenotypes contribute to different ECM pheno-
types, degradation and accumulation or contraction of ECMs,
respectively, and their ECM modification can be reversed by the
use of specific protease and ROCK inhibitors, respectively.
In conclusion, we have shown for the first time using a
physiologically relevant 3D model that ovarian tumors cells that
present epithelial characteristics tend to penetrate/invade the
mesenchymal ECM as clusters or groups and use proteases to
degrade the matrix. On the other hand, cells that present partial
EMT phenotypes may push through the ECM by mechanisms
that are based on Rho-dependent ECM accumulation or
contraction and are less dependent on proteolysis for their
penetration/invasion. Our study also expands upon the view that
many cell types including tumor cells naturally penetrate through
ECMs while invading without the use of classic EMT mechanisms.
Our study suggests that differential ECM modification mecha-
nisms by various ovarian tumor cell lines may reflect heterogeneity
among tumors from different patients or within a given tumor.
Therefore, fully characterizing the potential invasion mechanisms
may help to design therapies targeting theses ovarian cancer cell
behaviors.
Materials and Methods
Cell cultures
NIH-3T3 fibroblast (N3Fs, originally obtained from ATCC)
were pre-conditioned in media containing 10% fetal bovine serum
(FBS) during serially cultivating for at least 22 passages [28,29]
before the use for 3D matrix production and maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin. Primary fibroblasts [28] were isolated from mouse
skin tumor induced by two stage carcinogenesis regimen and
characterized as tumor-associated fibroblast (TAF) [28,31]. These
TAFs (passage 5 to 7) were maintained in the same medium as
above. De-identified human ovarian tissue not required for
diagnosis was obtained from the FCCC Biosample Respository
following informed consent and HFNO402 and HFNO502
primary fibroblast cultures were derived as previously described
[63] under a protocol approved by the FCCC institutional review
board. The panel of ovarian tumor cell lines used consisted of
OVCAR2, OVCAR3, OVCAR4, OVCAR5, OVCAR10,
A2780, CP70, C30, PEO1, PEO4, SKOV3, and UPN251
[32,35,64]. All tumor cells were cultured in RPMI 1640 medium
supplemented with 10% FBS, 0.3 U/mL insulin, 2 mM L-
glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin.
All the cells were cultured in a humidified incubator at 37uC and
5% CO2. All the reagents formulated for media were purchased
from Mediatech, Inc. (Manassas, VA) except for insulin (Sigma-
Aldrich, St. Louis, MO).
Fibroblast-derived 3D matrix production
In vivo-like 3D matrices were derived from N3Fs (for the
majority of studies) or TAFs as previously described [28,29,30,31].
Briefly, cells were plated at the density of 2.5610
5 cells/mL and
treated with freshly prepared 50 mg/mL ascorbic acid every
48 hours for 6 days after they reached confluence. Following the
ascorbic acid treatment, fibroblasts were removed from the ECM
using phosphate buffered saline (PBS) containing 0.5% (v/v)
TritonH X-100 and 20 mM ammonium hydroxide (Sigma-
Aldrich). Resulting cell-free 3D matrices were washed and stored
in PBS supplemented with 100 U/mL penicillin and 100 mg/mL
streptomycin at 4uC until used.
Antibodies and inhibitors
Anti-E-cadherin (Clone 36), N-cadherin (32), and b1-integrin
(18) antibodies were obtained from BD Biosciences (San Diego,
CA) and used for immunofluorescence (IF) staining and immuno-
blotting analyses. Other antibodies used for immunoblot analysis
were pan-keratin (80, Abcam Inc., Cambridge, MA), vimentin
(VIM-13.2, Sigma-Aldrich), uPA (AB-2, NeoMarkers, Fremont,
CA), MT1-MMP (LEM-2/15.8, Chemicon International, Teme-
cula, CA), MMP-2 (polyclonal, Abcam Inc.), MMP-9 (GE-213,
Chemicon International), ZO-1 (Z-R1, Zymed, San Francisco,
CA), Claudin-1 (JAY.8, Zymed), Occludin-1 (OC-3F10, Zymed),
ZEB-1 (polyclonal, Bethyl Laboratories Inc., Montgomery, TX),
and GAPDH (Chemicon International). Protease inhibitors,
aprotinin, leupeptin, and amiloride were obtained from Sigma-
Aldrich and included in the media at concentrations of 7.5, 20,
and 100 mM, respectively. A broad spectrum inhibitor of MMP,
GM6001 (25 mM), and Rho Kinase inhibitors, Y27632 (25 mM),
and H1152 (0.1 mM) were purchased from EMD Chemicals, Inc
(Gibbstown, NJ). Monoclonal anti-b1 integrin (6S6, azide free) was
purchased from Chemicon International and added in culture
medium (0.5 mg/mL) to inhibit functional activity of b1-integrin.
The same concentration of mouse IgG (Chemicon International)
was used as a negative control. Concentration of inhibitors was
determined at the levels which did not significantly affect cell
viability in 2D culture using CellTiter Blue Cell Viability Assay
reagent (Promega, Madison, WI) and EnVision Mutilabel Plate
Reader (PerkinElmer, Waktham, MA).
ECM penetration/invasion assays
ECMs were derived from N3Fs or TAFs in 24-well plates and
stained with 1 mg/mL Alexa Fluor 555 carboxylic acid, succini-
midyl ester (Invitrogen, Carlsbad, CA) overnight, at 4uC and then
washed with PBS. Ovarian tumor cells (1,000 to 8,000 cells/well
depending on the cell line) were plated onto pre-stained matrices
and imaged every 2 days for 14 days after plating. Some matrices
were maintained with media in the absence of cells and served as
negative controls. Bright-field (cells) and fluorescence (matrices)
images were acquired using Nikon TE300 Inverted Fluorescent
Microscope (Nikon Inc., Melville, NY) equipped with image
acquisition and processing software, MetaVue (Molecular Devices,
Downingtown, PA). In order to track the same field over time, 9
randomly preselected fields per well were repeatedly imaged 0, 7,
and 10 days after plating cells. For penetration/invasion
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with freshly prepared media containing the inhibitors listed above
or their controls (e.g., water, dimethyl sulfoxide; DMSO, and IgG).
Inhibitor-containing media were replaced every 48 hours and
images were acquired at 7 days of culture. All the experiments
were conducted in duplicates and repeated at least three
independent times.
Indirect immunofluorescence staining
Tumor cells cultured within N3F-derived matrices were fixed in
4% paraformaldehyde, permeabilized with 100 mM digitonin, and
stained for b1 integrin, E-cadherin, and F-actin (phalloidin
conjugated to the tetramethyl rhodamine, Invitrogen). For fiber
detection of fibronectin (Abcam Inc.), 3D cultures were first
permeabilized with 4% paraformaldehyde containing 0.5%
TritonH X-100 for 3 minutes and then further fixed for
20 minutes using 4% paraformaldehyde containing 5% glucose.
Fixed/permeabilized samples were blocked using 5% BSA
dissolved in PBS. Following blocking, cover slips were incubated
with primary antibodies for 1 hour. Alexa Fluor 488 anti-rabbit
IgG or Alexa Fluor 594 anti-mouse IgG (Invitrogen) were used as
secondary antibodies. Immunostained cover slips were mounted
with Vectashield containing DAPI (Vector Laboratories, Inc,
Burlingame, CA) and visualized using Nikon Eclipse E800
Fluorescent Microscope.
Confocal microscopy and image analysis
Images were taken using Nikon TE2000 Eclipse Inverted
Microscope equipped with C1 scan head and operated by EZ-C1
software (Nikon Inc.). A minimum of five random fields per sample
were selected. Each field was scanned using a multiple focal plane
acquisition mode where images were taken at 0.5 mm intervals
using wavelengths corresponding to 405 (blue), 488 (green), and
561 nm (red), thus detecting nuclei, fibronectin, and total matrix
protein (TMP), respectively. MetaMorph (version 7.0, Molecular
Devices, Downingtown, PA) was used to acquire a maximum
intensity projection of a 3D image stack comprising of all focal
planes obtained from each field and to analyze images acquired.
Tumor cells present in the multilayer matrices were evaluated
using 90 degree reconstruction images. Cell behaviors within
ECMs in 3 different layers from the top to the bottom of the
matrices were also measured. From the original entire 3D
reconstruction image, z-planes were separately reconstituted to
represent ‘top,’ ‘middle,’ and ‘bottom’ fractions of the 3D cultures
as defined below. ‘Top,’ the plane on which one could start
detecting at least 20% of the field with stain-positive area for
fibronectin fibers and one additional plane below. ‘Bottom,’ the
plane where fibronectin staining is detected in an entire field and
one additional plane above. Finally, ‘middle,’ the one or two
halfway planes of all the planes encompassing from ‘top’ to
‘bottom’. Reconstituted images corresponding to each of these
three topographic fractions were pseudo-colored according to their
labeled (immunofluorescent) TMP or fibronectin intensities, which
ranged between 0 (the lowest) to 225 (the highest). Changes in
TMP or fibronectin induced by cells were estimated by calculating
the ratio of area (the total number of pixels) corresponding to
intensities that ranged between 90 and 225 (high intensity) relative
to areas with intensities below 90 (low intensity) in both cell-
containing and adjacent cell-absent areas in the same field. Cell-
induced intensity change was expressed as percent difference of
the ratio in cell-containing area relative to cell-absent area (100%).
Cell-containing areas were selected by manually circumventing
around cell clumps detected by cell nuclei (DAPI) staining using
original reconstituted projection image of the entire 3D culture in
each field and designated as ‘cell region’.
Immunoblot analysis
Cells cultured in 2D or under 3D (N3F-derived ECMs)
conditions were lysed using radioimmunoprecipitation assay buffer
(50 mM Tris HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 1%
NP40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented
with protease inhibitor cocktails (Sigma-Aldrich). Cell homoge-
nates were centrifuged at 10,0006g for 5 min at 4uC. Aliquots of
supernatant were mixed with sample loading buffer (50 mM Tris
buffer pH 6.8, 10% glycerol, 2% SDS, 5% b-mercaptoethanol,
and 0.02% bromophenol blue) and denatured at 95uC for 5 min.
Denatured proteins (35 mg/lane) were loaded onto 10% or 4–20%
NovexH Tris-Glycine gels (Invitrogen). After electrophoresis,
proteins were transferred onto nitrocellulose membranes and
probed with the indicated antibodies. Protein detection was
achieved using Western Lightning TM Plus-ECL Enhanced
Chemiluminescence Substrate (Perkin Elmer, Waltham, MA).
Protein concentration was measured using DC Protein Assay
reagents (Bio-Rad, Hercules, CA).
Gelatin and casein-plasminogen zymography
Cells were cultured in 2D or 3D (N3F-derived matrices)
conditions until they reached ,70% confluence and the media
was replaced with serum-free media for 48 hours. Supernatants
were concentrated by ultra-filtration using Amicon Ultra-15
centrifugal filter device (Millipore Corporation, Bedford, MA) at
3,0006g for 1 hour at 4uC. Concentrated samples (10 mg) were
subjected to non-reducing SDS-PAGE as described in the previous
study [50] using gels co-polymerized with 0.1% gelatin or 0.1%
casein and 10 mg/mL plasminogen (Sigma-Aldrich).
Statistical analyses
One-way analysis of variance (ANOVA) was used to compare
effect of different inhibitors on fibronectin or TMP intensity
change induced by cells using SAS software (version 9.2, SAS
Institute Inc, Cary, NC). Benjamin and Hochberg method was
used to control for the multiple comparisons and the false
discovery rate, which was controlled at 0.05. P-values smaller or
equal to 0.01 were considered significant. Data were converted to
log scale for analyses due to differences in the variance among
groups compared together.
Supporting Information
Figure S1 Expression of epithelial and mesenchymal markers in
OVCAR5 and OVCAR10 cells grown in 2D and 3D (N3F- and
TAF-derived matrices) conditions. Note that matrices (N3F and
TAF-derived) did not contribute to appreciable amount of any
proteins tested. For cell lysates obtained from 3D cultures,
matrices maintained without cells were used as controls to subtract
proteins derived from matrices.
(TIF)
Figure S2 Effect of various inhibitors on matrix remodeling
induced by OVCAR5 and OVCAR10 cells. OVCAR5 (A) and
OVCAR10 (B) cells were plated onto pre-labeled N3F-derived
matrices and cultured under various inhibitory conditions. Phase
contrast (cells, top panel) and fluorescence (matrices, bottom panel)
images were acquired at 7 days of culture. Bar represents 200 mm.
Concentrations of inhibitors used were selected to avoid noticeable
inhibition of cell proliferation. PI; a protease inhibitor cocktail of
individual protease inhibitors containing aprotinin (7.5 mM),
Invasion Mechanisms of Ovarian Tumor Cells in 3D
PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18872leupeptin (20 mM), and GM6001 (25 mM), PRI; a mixture of PI
and H1152 (0.1 mM).
(TIF)
Figure S3 Effect of aprotinin and H1152 on matrix remodeling
induced by cells with epithelial and partial EMT phenotypes.
OVCAR5-like cells, e.g., OVCAR5, OVCAR3, and OVCAR4
(A), and OVCAR10-like cells, e.g., OVCAR10, CP70, and C30
(B), were plated on pre-labeled N3F-derived matrices and cultured
in the absence or presence of aprotinin (7.5 mM) and H1152
(0.1 mM). Phase contrast (cells, top panel) and fluorescence
(matrices, bottom panel) images were acquired at 7 days of
culture. Bar represents 200 mm. Note that aprotinin effectively
inhibited ECM modification induced by OVCAR5, OVCAR3,
and OVCAR4 cells which degrade ECMs in contrast to
suppression of ECM contraction induced by OVCAR10, CP70,
and C30 cells by H1152.
(TIF)
Figure S4 Amiloride on caseinolytic activity derived from
OVCAR5 and OVCAR10 cells. Conditioned media derived from
3D (N3F-derived matrices) cultures of OVCAR5 and OVCAR10
cells were subjected to SDS-PAGE using gels copolymerized with
casein and plasminogen. Casein gels were incubated with
developing buffer for overnight at 37uC in the absence and
presence of an uPA inhibitor, amiloride. Note that caseinolytic
activity was retained even after the treatment of 1 mM amiloride.
(TIF)
Figure S5 ROCK activity in a panel of ovarian tumor cells.
Ovarian tumor cell lysates isolated from cells grown in 2D or 3D
(N3F-derived matrices) were subjected to an enzymatic immuno-
assay using ROCK Activity Assay Kit (see File S1 for details). Cells
were grouped according to their ECM remodeling capabilities as
shown in Figure 1. ROCK activity was expressed as units (in pg) of
purified active ROCKII.
(TIF)
File S1 Supplemental Methods.
(DOC)
Table S1 Intensity change of total matrix protein induced by
OVCAR5 cells in the presence and absence of various inhibitors
measured at the top, middle, and bottom parts of 3D culture.
(DOC)
Table S2 Intensity change of fibronectin induced by OVCAR5
cells in the presence and absence of various inhibitors measured at
the top, middle, and bottom parts of 3D culture.
(DOC)
Table S3 Intensity change of total matrix protein by OVCAR10
cells in the presence and absence of various inhibitors measured at
the top, middle, and bottom parts of 3D culture.
(DOC)
Table S4 Intensity change of fibronectin induced by OVCAR10
cells in the presence and absence of various inhibitors measured at
the top, middle, and bottom parts of 3D culture.
(DOC)
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